503039-57-4

Basic information

• Product Name: Benzoic acid, 4-[[(2-aminobenzoyl)amino]methyl]-
• CAS NO: 503039-57-4
• Molecular Formula: C15H14N2O3
• Molecular Weight: 270.288
• Mol File: 503039-57-4.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: Benzoic acid, 4-[[(2-aminobenzoyl)amino]methyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 4-[[(2-aminobenzoyl)amino]methyl]-(503039-57-4)
• EPA Substance Registry System: Benzoic acid, 4-[[(2-aminobenzoyl)amino]methyl]-(503039-57-4)

Safety Data

• Hazardous Substances Data: 503039-57-4(Hazardous Substances Data)

Upstream product

• 56-91-7 p-aminomethylbenzoic acid 
• 118-48-9 isatoic anhydride 

Downstream Products

• 1600529-85-8 4-((2-(2-naphthamido)benzamido)methyl)benzoic acid 
• 849235-59-2 4-((2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)methyl)benzoic acid 

Relevant articles and documents

Anthranilic acid derivatives as novel ligands for farnesoid X receptor (FXR)

Nuclear farnesoid X receptor (FXR) has important physiological roles in various metabolic pathways including bile acid, cholesterol and glucose homeostasis. The clinical use of known synthetic non-steroidal FXR ligands is restricted due to toxicity or poor bioavailability. Here we report the development, synthesis, in vitro activity and structure-activity relationship (SAR) of anthranilic acid derivatives as novel FXR ligands. Starting from a virtual screening hit we optimized the scaffold to a series of potent partial FXR agonists with appealing drug-like properties. The most potent derivative exhibited an EC50 value of 1.5 ± 0.2 μM and 37 ± 2% maximum relative FXR activation. We investigated its SAR regarding polar interactions with the receptor by generating derivatives and computational docking.

N-(2-Amino-phenyl)-4-(heteroarylmethyl)-benzamides as new histone deacetylase inhibitors

A variety of N-(2-amino-phenyl)-4-(heteroarylmethyl)-benzamides were designed and synthesized. These compounds were shown to inhibit recombinant human HDAC1 with IC50 values in the sub-micromolar range. In human cancer cells growing in culture these compounds induced hyperacetylation of histones, induced the expression of the tumor suppressor protein p21WAF1/Cip1, and inhibited cellular proliferation. Certain compounds of this class also showed in vivo activity in various human tumor xenograft models in mice.

Inhibitors of histone deacetylase

The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.